| Similar Articles |
|---|
 |
Bio-IT World
September 11, 2003
Malorye Branca |
The Odd Couple CombinatoRx brings matchmaking to drug discovery and development.   |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
BusinessWeek
June 13, 2005
Catherine Arnst |
Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins. |
BusinessWeek
June 16, 2011
Langreth & Cortez |
When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates. |
Chemistry World
March 27, 2013
Eugene Gerden |
Russian investment vehicle sets sights on innovative drugs Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs. |
BusinessWeek
May 21, 2007
Gene G. Marcial |
CombinatoRx Has A Rich Pipeline Even though CombinatoRx is tiny, the institutional big guns own stock. |
BusinessWeek
June 6, 2005
Catherine Arnst |
The Anti-Cancer Strategist Oncology specialist Judah Folkman pioneered a new treatment: Starve the tumor |
The Motley Fool
October 26, 2010
Ralph Casale |
Where We Are in the War on Cancer A summary of the roundtable discussions at Xconomy's recent event, "Boston's War on Cancer." |
Reason
April 2001
Ronald Bailey |
Goddamn the Pusher Man Why does everybody seem to hate the pharmaceutical industry? |
Chemistry World
September 7, 2015 |
Cancer Drugs Fund axes 23 treatments The Cancer Drugs Fund, which covers the cost of some cancer treatments that are not currently available on the National Health Service, has cut 23 treatments -- involving 16 drugs. |
The Motley Fool
May 31, 2011
Brian Orelli |
Profit From This Growing Drug Trend Cancer drugs press on. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
Pharmaceutical Executive
November 1, 2014
Jill Wechsler |
Outrage Grows Over Drug Pricing Insurers, physicians attack high-cost therapies in anticipation of specialty drug surge. |
Chemistry World
August 23, 2012
Dean Baker |
Monopoly money It is remarkable that the system of patent support for prescription drug research has not become more of a policy issue. |
The Motley Fool
June 29, 2011
Brian Orelli |
Doubling Up in Biotech Lilly hits multiple targets with one drug. |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
BusinessWeek
June 6, 2005 |
Inside Judah Folkman's Lab The pioneering cancer researcher, Dr. Judah Folkman, talks about the path that led to his discoveries and about how much remains to be done |
Pharmaceutical Executive
September 1, 2006
Patrick Clinton |
From the Editor: Undecided People are buying drugs, because companies are selling drugs. Interfere with the selling process, and people won't buy as many drugs. |
The Motley Fool
September 12, 2005
M.D. Mitchell |
Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch. |
Chemistry World
June 22, 2011
Sarah Houlton |
US Approves Cancer Drugs Twice as Fast as Europe Cancer drugs are, on average, approved nearly twice as fast in the US than they are in Europe. |
BusinessWeek
June 6, 2005
Catherine Arnst |
Better Odds Against Breast Cancer New treatments for breast cancer are more effective, and easier to live with |
The Motley Fool
June 15, 2005
Brian Gorman |
Patented Drugs Fair Game in R&D The Supreme Court's ruling could be bad news for investors in small pharma and biotech. |
Pharmaceutical Executive
April 1, 2005 |
Thought Leader: Better Business: Balancing Benefit, Risk, and Cost An interview with author and Harvard Medical School professor Dr. Jerry Avorn on how losing track of patient welfare and failing to address important safety problems isn't just bad science and bad ethics, it's also bad business. |
Pharmaceutical Executive
May 1, 2005
Margaret Buck |
Legal: No Exception? An important legal loophole has made patented tools available for biotech research. Today, though, it appears to be closing. |
Pharmaceutical Executive
May 1, 2005
Jill Wechsler |
Washington Report: The Pendulum Swings FDA cracks down on safety. Haven't we been here before? Perhaps in the end, the public will have a better understanding of the dangers associated with all pharmaceuticals and how virtually impossible it is to guarantee a risk-free medical treatment. |
BusinessWeek
June 13, 2005
Arlene Weintraub |
Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances. |
Pharmaceutical Executive
May 1, 2005
Sarah Houlton |
Global Report: Iron Fist The United Kingdom is hardening its stance on pharma industry issues. |
